Designs and develops computer-controlled injection technologies. Commercializes these technologies for medical, dental, and cosmetic applications. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
There is growth, but not at top-of-the-class tempo.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 84% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $9.0M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $5.7M against $9.0M in annual sales.
The stock sits at $0.44. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, MLSS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MLSS’s sales are going backwards, and it closed last year at a loss. The road back runs through both.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (50/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.